Trial · NCT02511184
Results by group184
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 184
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicity (DLT) | Crizotinib + Pembrolizumab | 2 | Participants | ||
| Number of Participants With Dose-limiting Toxicity (DLT) | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | 2 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | All-causality AE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | All-causality AE | 7 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | All-causality SAE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | All-causality SAE | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | Crizotinib-related AE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Crizotinib-related AE | 7 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | Crizotinib-related SAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Crizotinib-related SAE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | Pembrolizumab-related AE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Pembrolizumab-related AE | 6 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | Pembrolizumab-related SAE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Pembrolizumab-related SAE | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | Grade 1 all-causality AE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Grade 1 all-causality AE | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | Grade 2 all-causality AE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Grade 2 all-causality AE | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib + Pembrolizumab | Grade 3 all-causality AE | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events | Crizotinib Monotherapy Followed by Crizotinib + Pembrolizumab | Grade 3 all-causality AE | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02511184/results